To the Editor: The recent article by Handelsman describes the pattern of testosterone prescribing in Australia from January 1992 to December 2010.1 The author concludes that the progressive increase in Pharmaceutical Benefits Scheme (PBS)-subsidised testosterone prescribing is likely to be due to promotion-driven prescribing for speculative, non-approved indications.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Handelsman DJ. Pharmacoepidemiology of testosterone prescribing in Australia, 1992–2010. Med J Aust 2012; 196: 642-645.
- 2. Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007 Intern Med J 2009; 39: 676-681.
- 3. Blick G, Khera M, Bhattacharya RK, et al. Testosterone replacement therapy outcomes among opioid users: the testim registry in the United States (TRiUS). Pain Med 2012; 13: 688-698. doi: 10.1111/j.1526-4637.2012.01368.x
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.